A Randomized, Double–Blind Trial Comparing Pegylated Interferon Alfa–2B to Interferon Alfa–2B As Initial Treatment for Chronic Hepatitis C
Karen L. Lindsay, CHRISTIAN G. TREPO, Tobias Heintges et al. · Hepatology · 2001
This international, randomized, active-controlled, parallel-group, double-blind dose-finding study compared peginterferon alfa-2b (PegIntron) to interferon alfa-2b for the initial treatment of compensated chronic hepatitis C. We randomly assigned 1,219 subjects to receive either the standard three-times-weekly (TIW) interferon alfa-2b dose (3 MIU) or the once-weekly (QW) peginterferon alfa-2b (0.5, 1.0, or 1.5 microg/kg). Subjects were treated for 48 weeks and then followed for an additional 24 weeks. All 3 peginterferon alfa-2b doses significantly (P < or =.042) improved virologic response rates (loss of detectable serum HCV RNA) after treatment and after follow-up, as compared with interferon alfa-2b. Unlike the end-of-treatment virologic response, the sustained virologic response rate was not dose-related above 1.0 microg/kg peginterferon alfa-2b because of a higher relapse rate among patients treated with 1.5 microg/kg peginterferon alfa-2b, particularly among patients infected with genotype 1. All 3 peginterferon alfa-2b doses decreased liver inflammation to a greater extent than did interferon alfa-2b, particularly in subjects with sustained responses. No new adverse events were reported, and the majority of adverse events and changes in laboratory values were mild or moderate. In conclusion, peginterferon alfa-2b maintained (0.5 microg/kg) or surpassed (1.0, 1.5 microg/kg) the clinical efficacy of interferon alfa-2b while preserving its safety profile. The higher rate of virologic response during treatment with 1.5 microg/kg peginterferon alfa-2b in patients infected with genotype 1 and high viral levels warrants further evaluation.
Cited by 668 works. doi:10.1053/jhep.2001.26371
Authors
- Karen L. Lindsay
- CHRISTIAN G. TREPO
- Tobias Heintges
- Mitchell L. Shiffman
- Stuart C. Gordon
- John Carl Hoefs
- Eugene R. Schiff
- Zachary D Goodman
- Mark Laughlin
- Ruji Yao
- Janice K. Albrecht
References
- Reporting results of cancer treatment
- Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis†
- Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial
- Interferon Alfa-2b Alone or in Combination with Ribavirin as Initial Treatment for Chronic Hepatitis C
- Randomised trial of interferon α2b plus ribavirin for 48 weeks or for 24 weeks versus interferon α2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus
- Peginterferon Alfa-2a in Patients with Chronic Hepatitis C
- Hepatitis C Viral Dynamics in Vivo and the Antiviral Efficacy of Interferon-α Therapy
- Peginterferon Alfa-2a in Patients with Chronic Hepatitis C and Cirrhosis
- Long-Term Histologic Improvement and Loss of Detectable Intrahepatic HCV RNA in Patients with Chronic Hepatitis C and Sustained Response to Interferon-α Therapy
- Genetic Heterogeneity of Hepatitis C Virus: Quasispecies and Genotypes